Biomarker analysis in a phase III study of pemetrexed-carboplatin versus etoposide-carboplatin in chemonaive patients with extensive-stage small-cell lung cancer.
Smit, E Socinski, M Mullaney, B Myrand, S Scagliotti, G Reck, M Ciuleanu, T Von Pawel, J Karaseva, N
Smit, E
Socinski, M
Mullaney, B
Myrand, S
Scagliotti, G
Reck, M
Ciuleanu, T
Von Pawel, J
Karaseva, N
Citations
Altmetric:
Abstract
Clinical results of a randomized phase III trial comparing pemetrexed-carboplatin (PC) with etoposide-carboplatin (EC) in chemonaive patients with extensive-stage disease small-cell lung cancer (ED-SCLC) resulted in trial closure for futility; biomarker analyses using immunohistochemistry (IHC) and single-nucleotide polymorphisms (SNPs) are described herein.
Description
Date
2012-07
Publisher
Collections
Keywords
Type
Article
Citation
Biomarker analysis in a phase III study of pemetrexed-carboplatin versus etoposide-carboplatin in chemonaive patients with extensive-stage small-cell lung cancer. 2012, 23 (7):1723-9 Ann Oncol